TrueBeam STx, an advanced cancer treatment system offers patients a nonsurgical, specialized form of treatment that can be completed in five or even fewer outpatient sessions, with each lasting 20 minutes or less than that.
MUSC Hollings Cancer Center, in partnership with national radiosurgery provider Alliance Oncology, has invested in the new technology.
The new system will be used to treat patients with stereotactic radiosurgery, a noninvasive method of treating tumors with high-dose radiation appropriately matched to the size and shape of the tumor.
TrueBeam STx helps in minimizing radiation exposure to healthy tissue and allows doctors to offer customized treatment depending on the nature of cancer.
TrueBeam can treat cancerous and noncancerous tumors in the body, including the lung, brain, prostate, spine, liver, pancreas, kidney, bone and eye.
In addition, it can treat certain blood vessel abnormalities, as well as trigeminal neuralgia, a neuropathic disorder that causes intense facial pain.
MUSCHollings Cancer Center Department of Radiation Oncology chairman Joseph Jenrette III said the TrueBeam STx will allow to enhance the patient experience by significantly reducing treatment time to five or fewer visits.
"TrueBeam STx can give hope to patients with inoperable or surgically complex tumors, as well as those seeking an alternative to surgery or conventional radiation therapy," Jenrette III added.
Image: The treatment room at MUSC Health’s Department of Radiation Oncology containing state-of-the-art TrueBeam STx technology. Photo: courtesy of PRNewsFoto/MUSC Hollings Cancer Center.
